N-<2-Methyl-1-phenylpropyl>formamide | 109054-00-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-<2-Methyl-1-phenylpropyl>formamide
• 英文别名: 1-Phenyl-1-formylamino-2-methylpropan；N-(2-methyl-1-phenylpropyl)formamide
• CAS: 109054-00-4
• 化学式: C₁₁H₁₅NO
• 分子量: 177.246
• InChiKey: YDDQVIIOMOHHSP-UHFFFAOYSA-N

物化性质

• 沸点：
  331.5±21.0 °C(Predicted)
• 密度：
  0.989±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-<2-Methyl-1-phenylpropyl>formamide 在 盐酸 作用下， 反应 1.0h， 生成 2-甲基-1-苯丙胺
  参考文献：
  名称：

  通过形成非对映异构盐形成的外消旋体经典拆分方法的Dutch Resolution变体：成核抑制中的家族行为。

  摘要：

  外消旋物通过其非对映异构体盐的拆分可通过添加少量合适的成核抑制剂而受到积极影响。该发现是“荷兰解决方案”的逻辑扩展，其中使用了等摩尔量的相同家族的拆分试剂（即，结构上相关的拆分试剂）。我们进行了系统的研究，以寻找拆分剂1-苯基乙胺的成核抑制剂。研究了与1-苯基乙胺可能具有家族相似性的多种胺。发现（R）-1-苯基丁胺是（R）-1-苯基乙胺的良好抑制剂。浊度测量结果表明，对于扁桃酸拆分的模型情况，该抑制剂的主要作用是扩大了可溶性更高的非对映异构体的亚稳区域。该观察结果与以前的经验一致。对可能的家庭成员的进一步调查发现，抑制剂的有效性存在很大差异，具体取决于其结构。迄今为止，最有效的抑制剂是双官能的1-苯基乙胺和/或1-苯基丁胺类似物。发现外消旋抑制剂的作用接近与用于拆分的1-苯基乙胺的绝对构型相同的对映体纯抑制剂的作用。测试了最有效的抑制剂可解决多种外消旋物的结构，并显示了广泛的适用性。迄今为

  DOI：

  10.1002/chem.200500440
• 作为产物：
  描述：

  异丁酰苯 在 甲酸 、 formamide 作用下， 以 苯 为溶剂， 反应 2.0h， 生成 N-<2-Methyl-1-phenylpropyl>formamide
  参考文献：
  名称：

  Cervinka,O.; Fusek,J., Collection of Czechoslovak Chemical Communications, 1973, vol. 38, p. 441 - 446

  摘要：

  DOI：

文献信息

• [EN] BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES BICYCLIQUES ET LEUR UTILISATION EN TANT QUE MODULATEURS DE GPR119
  申请人：SCHERING CORP

  公开号：WO2009143049A1

  公开（公告）日：2009-11-26

  The present invention relates to Bicyclic Heterocycle Derivatives of formula (I), compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR1 19 in a patient.

  本发明涉及公式（I）的双环杂环衍生物，包含双环杂环衍生物的组合物，以及使用双环杂环衍生物治疗或预防患者的肥胖、糖尿病、代谢紊乱、心血管疾病或与GPR119活性相关的疾病的方法。
• Reactions of 1-acylamino-1-(trimethylsiloxy)alkanes: versatile precursors to acylimines
  作者：A. Peter Johnson、Richard W. A. Luke、Andrew N. Boa

  DOI：10.1039/p19960000895

  日期：——

  1-Acylamino-1-(trimethylsiloxy)alkanes react with carbon and heteroatom nucleophiles to give the corresponding 1-substituted-1-acylaminoalkanes. The 1-acylamino-1-(trimethylsiloxy)alkanes can also give rise to enamides, and by this route the mild antibiotic tuberin, and the isomeric (Z)-tuberin have been prepared. A further example of their reactions is illustrated with the acid-catalysed intramolecular cyclisation onto a carbon–carbon double bond. These transformations show that 1-acylamino-1-(trimethylsiloxy)alkanes are versatile precursors to synthetically useful acylimines.

  1-酰氨基-1-(三甲基硅氧基)烷烃与碳和杂原子亲核试剂反应，生成相应的1-取代-1-酰氨基烷烃。1-酰氨基-1-(三甲基硅氧基)烷烃还可以生成烯酰胺，通过这种途径，可以制备出温和的抗生素肽霉素及其异构体(Z)-肽霉素。它们反应的另一个例子是酸催化的分子内环化反应，发生在碳-碳双键上。这些转化表明，1-酰氨基-1-(三甲基硅氧基)烷烃是合成有用酰亚胺的多功能前体。
• Condensation of N,N-bis(trimethylsilyl)formamide with aldehydes: a general method for the synthesis of 1-formamido-1-trimethylsilyloxyalkanes
  作者：A. Peter Johnson、Richard W. A. Luke、Robert W. Steele

  DOI：10.1039/c39860001658

  日期：——

  Reaction of bis(trimethylsilyl)formamide with simple aldehydes gives 1-formamido-1-trimethylsilyloxyalkanes (and the corresponding adducts with ketones), which undergo displacement of trimethylsilanol by a variety of nucleophiles to give α-substituted amides.

  双（三甲基甲硅烷基）甲酰胺与简单的醛反应，生成1-甲酰胺基-1-三甲基甲硅烷基氧基烷烃（以及与酮的相应加合物），然后通过各种亲核试剂取代三甲基甲硅烷醇，得到α-取代的酰胺。
• BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS
  申请人：Harris Joel M.

  公开号：US20110065671A1

  公开（公告）日：2011-03-17

  The present invention relates to Bicyclic Heterocycle Derivatives of formula (I), compositions comprising a Bi-cyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR1 19 in a patient.

  本发明涉及式(I)的二环杂环衍生物，包括一种二环杂环衍生物的组合物，并且还涉及使用这些二环杂环衍生物来治疗或预防患者的肥胖症、糖尿病、代谢障碍、心血管疾病或与GPR1 19活性相关的疾病的方法。
• Synthesis and structure–activity relationships of potential anticonvulsants based on 2-piperidinecarboxylic acid and related pharmacophores
  作者：Bin Ho、A Michael Crider、James P Stables

  DOI：10.1016/s0223-5234(00)01206-x

  日期：2001.3

  Using N-(2,6-dimethyl)phenyl-2-piperidinecarboxamide (1) and N-(alpha -methylbenzyl)-2-piperidinecarboxamide (2) as structural leads, a variety of analogues were synthesised and evaluated for anticonvulsant activity in the MES test in mice. In the N-benzyl series, introduction of 3-Cl, 4-Cl, 3,4-Cl-2, or 3-CF3 groups on the aromatic ring led to an increase in MES activity. Replacement of the alpha -methyl group by either i-Pr or benzyl groups enhanced MES activity with no increase in neurotoxicity. Substitution on the piperidine ring nitrogen led to a decrease in MES activity and neurotoxicity, while reduction of the amide carbonyl led to a complete loss of activity. Movement of the carboxamide group to either the 3- or 4-positions of the piperidine ring decreased MES activity and neurotoxicity. Incorporation of the piperidine ring into a tetrahydroisoquinoline or diazahydrinone nucleus led to increased neurotoxicity. In the N-(2,6-dimethyl)phenyl series, opening of the piperidine ring between the 1- and 6-positions gave the active norleucine derivative 75 (ED50 = 5.8 mg kg(-1), TD50 = 36.4 mg kg(-1), PI = 6.3). Replacement of the piperidine ring of I by cycloalkane (cyclohexane, cyclopentane, and cyclobutane) resulted in compounds with decreased MES activity and neurotoxicity, whereas replacement of the piperidine ring by a 4-pyridyl group led to a retention of MES activity with a comparable PI. Simplification of the 2-piperidinecarboxamide nucleus of 1 into a glycinecarboxamide nucleus led to about a six-fold decrease in MES activity. The 2,6-dimethylanilides were the most potent compounds in the MES test in each group of compounds evaluated, and compounds 50 and 75 should be useful leads in the development of agents for the treatment of tonic-clonic and partial seizures in man. (C) 2001 Editions scientifiques et medicales Elsevier SAS.